Probability-based approaches for identifying low-titer antibody responses against SARS-CoV-2

Xaquín Castro Dopico[1#], Leo Hanke[1°], Daniel J. Sheward[1°], Sandra Muschiol[2], Soo Aleman[3], Nastasiya F. Grinberg[4], Monika Adori[1], Murray Christian[1], Laura Perez Vidakovics[1], Changil Kim[1], Sharesta Khoenkhoen[1], Pradeepa Pushparaj[1], Ainhoa Moliner Morro[1], Marco Mandolesi[1], Marcus Ahl[3], Mattias Forsell[5], Jonathan Coquet[1], Martin Corcoran[1], Joanna Rorbach[6,7], Joakim Dillner[8], Gordana Bogdanovic[2], Gerald M. McInerney[1], Tobias Allander[1,2], Ben Murrell[1], Chris Wallace[4,9], Jan Albert[1,2], Gunilla B. Karlsson Hedestam[1#]

Affiliations:
[1]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
[2]Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
[3]Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
[4]Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW
[5]Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden
[6]Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden
[7]Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden
[8]Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge 141 52, Sweden
[9]MRC Biostatistics Unit, University of Cambridge CB2 0SR, United Kingdom

°Equal contribution
#Correspondence

Abstract

The levels of the antibody response against SARS-CoV-2 varies widely between individuals, which together with the decline of antibody responses over time, complicates the correct classification of seropositivity using conventional assay cut-offs. All subjects in a cohort of SARS-CoV-2 PCR+ individuals representing different disease severity categories (n=105), and a group of PCR+ hospital staff (n=33), developed IgG against pre-fusion-stabilized spike (S) trimers and 97% did against the receptor-binding domain (RBD). The levels differed by several orders of magnitude and associated with disease phenotype. Concomitant analysis of a cohort of healthy blood donors and pregnant women (n=1,000), representing individuals who had undergone milder infections, demonstrated highly variable IgG titers, including several that scored between the classical 3SD and 6SD cut-offs. Since the correct classification of seropositivity is critical for epidemiological estimates, we trained probabilistic algorithms to assign likelihood of past infection using anti-S and -RBD IgG data from PCR+ individuals and a large cohort of historical negative controls (n=595). Applied to blood donors and pregnant women, this probabilistic approach provided a more accurate way to interpret antibody titers spread over a large continuum offering a probability-based diagnosis. The methods described here are directly applicable to serological measurements following natural infection and vaccination.

Introduction

The characterization of nascent SARS-CoV-2-specific antibody responses is critical to our understanding of the infection at both individual and population levels[1]. While several studies have reported antibody phenotypes of SARS-CoV-2 infection, consensus on several key issues remains outstanding, such as whether all persons who have had the infection develop antibody responses to the virus, what the duration of these responses are following peak responses and what levels provide protective immunity against re-infection[2–6].

Because serological studies have such a central role, both in immunosurveillance and for our basic understanding of how humans respond to infection, there is a pressing need for robust and reproducible platforms - and statistical tools - to examine antibody titers of varying levels, as highlighted by the current SARS CoV-2 pandemic[7]. Antibody responses to the virus spike glycoprotein are particularly relevant as spike-directed specificities mediate virus neutralizing activity. The great majority of COVID-19 vaccines are based on the spike surface antigen as the goal is to induce neutralizing antibodies that block virus entry into Ace2-positive target cells[8,9]. There is, therefore, a great need for well-validated assays to monitor both infection and immunization-induced antibody responses against SARS-CoV-2 spike, and this will increase further as different spike-based vaccines are introduced world-wide and follow-up studies are undertaken to understand the magnitude and quality of responses in different target groups.

To meet this need, we developed highly sensitive and specific IgM, IgG and IgA ELISAs based on mammalian cell-expressed pre-fusion-stabilized soluble trimers of the SARS-CoV-2 spike (S) glycoprotein and the receptor-binding domain (RBD), and used them in tandem to survey serum samples from large cohort of individuals PCR+ for SARS-CoV-2. For a robust validation of the assays, we used a large set of serum samples from historical blood donors as negative controls (*n*=595), which is critical for determining the assay background. We then applied these assays to blood donors and pregnant women for whom serostatus was unknown.

As we show, and as has been reported by others[3,10], the magnitude of response varied greatly between individuals and was associated with disease severity. Those with most pronounced symptoms, as observed in our cohort of hospitalized patients, tended to have very high anti-viral antibody titers, while those with asymptomatic or mild disease, represented by randomly sampled blood donors and pregnant women, exhibited a range of antibody levels, some of

which were high and others that were close to the negative control serum samples, complicating

their correct classification.

To improve upon the dichotomization of a continuous variable – which is common to many

clinical tests but generally results in a loss of information[11,12] – we used tandem anti-S and

RBD IgG data from confirmed infections and negative controls to train different probabilistic

approaches to identify likelihood of past infection. Compared to strictly thresholding the assay

based on standard 3SD or 6SD cut-offs, the more quantitative approaches modelled the

probability a sample was positive from training responses, improving the identification of low

titer values.

Results

Study samples are detailed in Table 1.

<u>Antibody test development</u>

We developed ELISA protocols to profile IgM, IgG and IgA specific for a pre-fusion

conformation stabilized spike (S) glycoprotein trimer[13], the RBD, and the viral nucleocapsid

(N). Trimer conformation was confirmed in each batch by cryo-EM[14] and a representative

subset of study samples was used for assay development (Fig. S1A). No reproducible IgG

reactivity to S or RBD was observed across all 595 historical controls in the study, although

two individuals who were PCR-positive for endemic coronaviruses (ECV+) in the last six

months displayed robust IgM reactivity to both SARS-CoV-2 N and S, and two 2019 blood

donors (from $n=72$ tested) had low anti-S IgM reactivity (Fig. S1B). Thus, further investigation

is required to establish the contribution of potential cross-reactive memory SARS-CoV-2

responses[15].

Our assay revealed a greater than 1,000-fold difference in anti-viral IgG titers between Ab-

positive individuals when examining serially diluted sera, a wide range difficult to capture in a

single test (Fig. S1C). In SARS-CoV-2 PCR+ individuals, anti-viral IgG titers were

comparable for S (EC_{50}=3,064; 95% CI [1,197 - 3,626]) and N (EC_{50}=2,945; 95% CI [543 -

3,936]) and lower for RBD [EC_{50}=1,751; 95% CI 966 - 1,595]. A subset (*ca.* 10%) of the

SARS-CoV-2-confirmed individuals did not have detectable IgG responses against the SARS

CoV-2 nucleocapsid protein (N) (Fig. S1C), as previously reported[16]. Therefore, we did not

explore responses to N further.

<u>Elevated anti-viral Ab titers and neutralizing responses are associated with increased disease</u>

<u>severity</u>

When screening all SARS-CoV-2 PCR+ individuals from whom clinical information was

available ($n=105$), we detected potent IgG responses against S in 100% of participants, and

against RBD in 97% of persons. IgM and IgA responses were generally weaker and more

variable and also spread over a large range (Fig. 1A).

To examine this further, PCR+ individuals were classified according to their clinical status as

follows: non-hospitalized; hospitalized or admitted to the intensive care unit. Serum IL-6

levels, a cytokine that feeds Ab production[17–20], were increased in severe disease samples (Fig.

1B). Furthermore, multivariate analyses revealed increased anti-viral IgM, IgG and IgA to also

be associated with disease severity, as has been reported[3], although IgM was reduced in

intensive care samples, compared to hospitalized patients (Fig. 1C and S1D-E, Table S1).

Severe disease was most associated with virus-specific IgA, suggestive of mucosal pathology.

We did not observe an association between ICU or IL-6 status and IgM levels, supporting that

levels of the cytokine and IgA mark a more severe clinical course of COVID-19 (Fig. S1D).

IgA anti-RBD responses were lower in non-hospitalized and hospitalized females compared to

males, trending similarly for S (Table S1)[10].

Across all PCR+ individuals (sampled up to two months from PCR test), anti-viral IgG levels

were maintained, while IgM and IgA decreased, in agreement with their circulating $t_{1/2}$ and

viral clearance (Table S1). In longitudinal patient samples (sequential sampling of PCR+

individuals in the study) where we observed seroconversion, IgM, IgG and IgA peaked with

similar kinetics when all three isotypes developed, although IgA was not always generated in

non-hospitalized or hospitalized individuals (Fig 1D), supporting a more diverse antibody

response in severe disease.

To extend these observations, we characterized the virus neutralizing Ab response in PCR+

patients. Using a robust *in vitro* pseudotype virus neutralization assay[21], we detected

neutralizing antibodies in the serum of all SARS-CoV-2 PCR+ individuals (from $n=48$).

Neutralizing responses were not seen in samples before seroconversion (Fig. 1D) or negative controls. A large range of neutralizing ID_{50} titers was apparent, with binding and neutralization being highly correlated (Fig. S1D). In agreement with the binding data, the strongest neutralizing responses were observed in samples from patients in intensive care (g.mean ID_{50}=5,058; 95% CI [2,422 - 10,564]) (Fig 1E).

In healthy blood donors and pregnant women (*n*=1,000 collected between weeks 17-21, 2020), who did not have signs or symptoms of COVID-19 when they were sampled or two weeks prior to sampling, and had no history of being hospitalized for COVID-19, IgG titers varied greatly but were generally lower than hospitalized COVID-19 patients (Fig. 1F).

Probabilistic analyses of positivity

As SARS-CoV-2 results in asymptomatic or mild disease in the majority of cases, and antibody titers decline following peak responses, the detection of low titer values is critical to individual and population-level estimates of antibody-positivity. Indeed, many healthy donor test samples screen in this study had optical densities between the 3 and 6 SD cut-offs for both or a single antigen (Fig. 1E), highlighting the problem of assigning case to *low responder* values.

To improve our understanding of the assay boundary, we repeatedly analyzed a large number of historical (SARS-CoV-2-negative) controls (blood donors from the spring of 2019, *n*=595) alongside test samples throughout the study (Fig. 2A). We considered the spread of known negative values critical, since the use of a small and unrepresentative set of controls can lead to an incorrectly set threshold, which skews the seropositivity estimate. This is illustrated by the random sub-sampling of non-overlapping groups of negative controls, resulting in a 40% difference in the positivity estimate (Fig. 2B).

To exploit individual titers and further improve our statistical estimates, we used anti-S and RBD data from PCR+ individuals and negative controls to train probabilistic algorithms to assign likelihood of past infection. A small cohort of PCR+ individuals among Karolinska University Hospital staff (*n*=33) provided additional training values four months post-PCR test.

To this end, we compared different probabilistic algorithms – namely, logistic regression

(LOG), linear discriminant analysis (LDA), linear support vector machines (SVM) and

quadratic SVM (SVM2) – suited to ELISA data (Fig. 2C, Materials and Methods). Using ten-

fold cross validation and training models on both proteins simultaneously (S and RBD), we

found all methods worked well, with sensitivity >98% and specificity >99.6% (Fig. 2D). On

this metric, LDA gave the highest specificity. Logistic regression had similarly high specificity

on some folds of the training data, but with higher sensitivity. We deliberately considered

balanced and unbalanced folds (where case:control ratios varied between folds) and found

LOG showed the least consistency across strategies, which reflects that the proportion of cases

in a sample directly informs a logistic model's estimated parameters. SVM methods had lower

specificity than LDA in the training data, but higher sensitivity.

The standard methods, calling positives by a fixed number of SD above the mean of negative

controls, displayed two extreme behaviors: 3-SD had the highest sensitivity (100%) while 6-

SD had the highest specificity, and the lowest sensitivity (Fig. 2D), emphasizing that the

number of SD above the mean is a key parameter, but one which is not learnt in any formal

data-driven manner. Both SVM and LDA offer linear classification boundaries, but we can see

that the probability transition from negative to positive cases is much sharper for LDA (Fig.

2C) – potentially resulting in false negatives when applied to the test data, but giving the model

high specificity in the training data under cross-validation. SVM exhibits a softer probability

transition around its classification boundary, offering a much more nuanced approach to the

points lying in the mid-range of the two proteins. SVM2 creates a nonlinear boundary, but the

cross validation suggested that this didn't improve performance relative to linear SVM.

We chose to create ensemble learners, which were an unweighted average of SVM (linear) or

SVM2 (quadratic) and LDA (*ENS* and *ENS2*, respectively), as well as a LOG-LDA learner, to

balance the benefits of each approach. The ensemble learners seemed to combine the benefits

of their parent methods (Fig. 2C). Test data points in the lower right region of each plot are the

hardest to classify due to the relative scarcity of observations in this region in the training

dataset and *ENS* (SVM-LDA) showed the greatest uncertainty in these regions, appropriately.

Given these results, we chose to use *ENS* (SVM-LDA), with an average sensitivity >99.1% and

specificity >99.8%, to analyze the test data.

When applied to serology data, the output of *ENS* is the probability of each sample being antibody-positive. In healthy donor test data, the *ENS* learner (considering S and RBD responses in an individual sample) estimated 7.8% (95% CI [4.8-12.5]) positivity in samples collected in week 21 of 2020 (Fig. 2E, Table S2). This is in contrast to the SD thresholding, which identified 12% and 10% positivity for S and RBD, respectively at 3 SD, and 8% and 7.5, respectively at 6 SD at this time point (Table S2). Therefore, apart from providing more accurate population-level estimates, critical to seroprevalence studies, these approaches have the potential to provide more nuanced information about titers to an individual after an antibody test. For example, the test samples with a 30-60% chance of being antibody positive (Fig. 2E) can be targeted for further investigation. Moreover, such tools are applicable to other clinical metrics where a continuous scale is dichotomized and all data and code for implementation is freely available via our online repositories.

Discussion

Benefitting from a robust antibody test developed alongside a diagnostic clinical laboratory responsible for monitoring sero-reactivity during the pandemic, we profiled SARS-CoV-2 antibody responses in three cohorts of clinical interest. COVID-19 patients receiving intensive care showed the highest anti-viral Ab titers, developing augmented serum IgA and IL-6 with worsening disease and more advance respiratory and/or gastrointestinal pathology. These results demonstrate the inflammatory nature of severe COVID-19, and support that cytokine and isotype-level measures can help patient monitoring[22].

Importantly, our neutralization data illustrated that nearly all SARS-CoV-2 PCR+ individuals and healthy donors who seroconverted developed neutralizing antibodies capable of preventing S-mediated cell entry, albeit at different titers. These data support that SARS-CoV-2 infection generates a functional B cell response in the majority of people[6] and serve as a useful comparator to titers in response to vaccination.

Outside of the severe disease setting, it is critical to accurately determine who and how many people have seroconverted for clinical and epidemiological reasons. However, this is complicated by low titer values, which in some cases – and increasingly with time since exposure and in mild disease[23,24] – overlap outlier values among negative control samples. Test samples with true low anti-viral titers fall into this range, highlighting the need to better

understand the assay boundary. To improve upon strictly thresholding the assay, we developed probabilistic approaches that characterized uncertainty in individual measures. These and related approaches provide more statistically sound measurements at the level of cohorts and the potential to communicate more nuanced information to individual patients - although the communication of probability needs to be approached with care to ensure what is described matches what an individual interprets. Furthermore, such approaches will aid longitudinal studies of the duration of immunity after SARS-CoV-2 spike-based vaccines and natural infection and facilitate the comparison of responses between different cohorts.

Materials and methods

Human samples and ethical declaration

Samples from PCR+ individuals and admitted COVID-19 patients (n=105) were collected by the attending clinicians and processed through the Departments of Medicine and Clinical Microbiology at the Karolinska University Hospital. Samples were used in accordance with approval by the Swedish Ethical Review Authority (registration no. 2020-02811). All personal identifiers were pseudo-anonymized, and all clinical feature data were blinded to the researchers carrying out experiments until data generation was complete. PCR testing for SARS-CoV-2 RNA was by nasopharyngeal swab or upper respiratory tract sampling at Karolinska University Hospital. As viral RNA levels were determined using different qPCR platforms (with the same reported sensitivity and specificity) between participants, we did not analyze these alongside other features. PCR+ individuals (n=105) were questioned about the date of symptom onset at their initial consultation and followed-up for serology during their care, up to 2 months post-diagnosis. Serum from SARS-CoV-2 PCR+ individuals was collected 6-61 days post-test, with the median time from symptom onset to PCR being 5 days. In addition, longitudinal samples from 10 of these patients were collected to monitor seroconversion and isotype persistence.

Hospital workers at Karolinska University Hospital were invited to test for the presence of SARS-CoV-2 RNA in throat swabs in April 2020 and virus-specific IgG in serum in July 2020. We screened 33 PCR+ individuals to provide additional training data for ML approaches. All participants provided written informed consent. The study was approved by the National Ethical Review Agency of Sweden (2020-01620) and the work was performed accordingly.

Anonymized samples from blood donors (n=100/week) and pregnant women (n=100/week) were randomly selected from their respective pools by the department of Clinical Microbiology, Karolinska University Hospital. No metadata, such as age or sex information were available for these samples in this study. Pregnant women were sampled as part of routine for infectious diseases screening during the first trimester of pregnancy. Blood donors (n=595) collected through the same channels a year previously were randomly selected for use as negative controls. Serum samples from individuals testing PCR+ for endemic coronaviruses, 229E, HKU1, NL63, OC43 (n=20, ECV+) in the prior 2-6 months, were used as additional negative controls. The use of study samples was approved by the Swedish Ethical Review

296   Authority (registration no. 2020-01807). Stockholm County death and Swedish mortality data
297   was sourced from the ECDC and the Swedish Public Health Agency, respectively. Study
298   samples are defined in Table 1.
299
300   Serum sample processing
301   Blood samples were collected by the attending clinical team and serum isolated by the
302   department of Clinical Microbiology. Samples were anonymized, barcoded and stored at -20°C
303   until use. Serum samples were not heat-inactivated for ELISA protocols but were heat-
304   inactivated at 56°C for 60 min for neutralization experiments.
305
SARS-CoV-2 antigen generation
The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain with a
C-terminal T4 fibritin trimerization motif was obtained from[13]. The plasmid was used to
transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent (Thermo Fisher
Scientific). The ectodomain was purified from filtered supernatant on Streptactin XT resin
(IBA Lifesciences), followed by size-exclusion chromatography on a Superdex 200 in 5 mM
Tris pH 8, 200 mM NaCl.
313
314   The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned upstream of a Sortase A
315   recognition site (LPETG) and a 6xHIS tag, and expressed in 293F cells as described above.
316   RBD-HIS was purified from filtered supernatant on His-Pur Ni-NTA resin (Thermo Fisher
317   Scientific), followed by size-exclusion chromatography on a Superdex 200. The nucleocapsid
318   was purchased from Sino Biological.
319
Anti-SARS-CoV-2 ELISA
96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S trimers, RBD or
nucleocapsid (100 μl of 1 ng/μl) in PBS overnight at 4°C. Plates were washed six times with
PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk. Human serum samples were
thawed at room temperature, diluted (1:100 unless otherwise indicated), and incubated in
blocking buffer for 1h (with vortexing) before plating. Serum samples were incubated
overnight at 4°C before washing, as before. Secondary HRP-conjugated anti-human antibodies
were diluted in blocking buffer and incubated with samples for 1 hour at room temperature.
Plates were washed a final time before development with TMB Stabilized Chromogen
(Invitrogen). The reaction was stopped using 1M sulphuric acid and optical density (OD)

values were measured at 450 nm using an Asys Expert 96 ELISA reader (Biochrom Ltd.).

Secondary antibodies (all from Southern Biotech) and dilutions used: goat anti-human IgG

(2014-05) at 1:10,000; goat anti-human IgM (2020-05) at 1:1000; goat anti-human IgA (2050-

05) at 1:6,000. All assays of the same antigen and isotype were developed for their fixed time

and samples were randomized and run together on the same day when comparing binding

between PCR+ individuals. Negative control samples were run alongside test samples in all

assays and raw data were log transformed for statistical analyses.

In vitro virus neutralisation assay

Pseudotyped viruses were generated by the co-transfection of HEK293T cells with plasmids

encoding the SARS-CoV-2 spike protein harboring an 18 amino acid truncation of the

cytoplasmic tail[13]; a plasmid encoding firefly luciferase; a lentiviral packaging plasmid

(Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was changed 12-16 hours post-

transfection and pseudotyped viruses harvested at 48- and 72-hours, filtered through a 0.45 µm

filter and stored at -80°C until use. Pseudotyped neutralisation assays were adapted from

protocols validated to characterize the neutralization of HIV, but with the use of HEK293T-

ACE2 cells. Briefly, pseudotyped viruses sufficient to generate ~100,000 RLUs were incubated

with serial dilutions of heat-inactivated serum for 60 min at 37°C. Approximately 15,000

HEK293T-ACE2 cells were then added to each well and the plates incubated at 37°C for 48

hours. Luminescence was measured using Bright-Glo (Promega) according to the

manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration time of

0.3s. The limit of detection was at a 1:45 serum dilution.

IL-6 cytometric bead array

Serum IL-6 levels were measured in a subset of PCR+ serum samples (_n_=64) using an

enhanced sensitivity cytometric bead array against human IL-6 from BD Biosciences (Cat #

561512). Protocols were carried out according to the manufacturer's recommendations and

data acquired using a BD Celesta flow cytometer.

Statistical analysis of SARS-CoV-2 PCR+ data

All univariate comparisons were performed using non-parametric analyses (Kruskal-Wallis,

stratified Mann-Whitney, hypergeometric exact tests and Spearman rank correlation), as

indicated, while multivariate comparisons were performed using linear regression of log

transformed measures and Wald tests. For multivariate tests, all biochemical measures (IL-6,

PSV ID50 neut., IgG, IgA, IgM) were log transformed to improve the symmetry of the distribution. As "days since first symptom" and "days since PCR+ test" are highly correlated, we cannot include both in any single analysis. Instead, we show results for one, then the other (Supp. Table 1).

Probabilistic algorithms for classifying antibody positivity

Prior to analysis, each sample OD was standardized by dividing by the mean OD of "no sample controls" on that plate or other plates run on the same day. This resulted in more similar distributions for 2019 blood donor samples with 2020 blood donors and pregnant volunteers, as well as smaller coefficients of variation amongst PCR+ COVID patients for both SPIKE and RBD.

Our probabilistic learning approach consisted of evaluating different algorithms suited to ELISA data, which we compared through ten-fold cross validation (CV): logistic regression (LOG), linear discriminant analysis (LDA), support vector machines (SVM) with a linear kernel, and quadratic SVM (SVM2). Logistic regression and linear discriminant analysis both model log odds of a sample being case as a linear equation with a resulting linear decision boundary. The difference between the two methods is in how the coefficients for the linear models are estimated from the data. When applied to new data, the output of logistic regression and LDA is the probability of each new sample being a case. Support vector machines is an altogether different approach. We opted for a linear kernel, once again resulting in a linear boundary. SVM constructs a boundary that maximally separates the classes (i.e. the margin between the closest member of any class and the boundary is as wide as possible), hence points lying far away from their respective class boundaries do not play an important role in shaping it. SVM thus puts more weight on points closest to the class boundary, which in our case is far from being clear. Linear SVM has one tuning parameter C, a cost, with larger values resulting in narrower margins. We tuned C on a vector of values (0.001, 0.01, 0.5, 1, 2, 5, 10) via an internal 5-fold CV with 5 repeats (with the winning parameter used for the final model for the main CV iteration). We also note that the natural output of SVM are class labels rather than class probabilities, so the latter are obtained via the method of Platt[25].

We considered three strategies for cross-validation: i) random: individuals were sampled into folds at random, ii) stratified: individuals were sampled into folds at random, subject to ensuring the balance of cases:controls remained fixed and iii) unbalanced: individuals were

sampled into folds such that each fold was deliberately skewed to under or over-represent cases
compared to the total sample. We sought a method with performance that was consistently
good across all cross-validation sampling schemes, because the true proportion of cases in the
test data is unknown, and we want a method that is not overly sensitive to the proportion of
cases in the training data. We chose to assess performance using sensitivity and specificity, as
well as consistency.

Given the good performance of all learners (described in the results), we considered the
prediction surface associated with each SVM, LDA, SVM-LDA ensemble, and the standard 3-
SD, 6-SD hard decision boundaries. Note that while methods trained on both proteins can draw
decision contours at any angle, SD methods are limited to vertical or horizontal lines. We can
see that success, or failure, of the SD cut-offs depends on how many positive and negative
cases overlap for a given measure (S or RBD) in the training sample. In the training data the
two classes are nearly linearly separable when each protein is considered on its own, which
explains good performance of 3-SD and 6-SD thresholds. However, the test data contain many
more points in the mid-range of S-RBD, which makes hard cut-offs a problematic choice for
classifying test samples.

We trained the learners on all 733 training samples and used these to predict the probability of
anti-SARS-CoV-2 antibodies in blood donors and pregnant volunteers sampled in 2020. We
inferred the proportion of the sampled population with positive antibody status each week using
multiple imputation. We repeatedly (1,000 times) imputed antibody status for each individual
randomly according to the ensemble prediction, and then analyzed each of the 1,000 datasets
in parallel, combining inference using Rubin's rules, derived for the Wilson binomial
proportion confidence interval[26].

Data and code availability statement

Data generated as part of the study, along with custom code for statistical analyses, is openly
available via our GitHub repository: https://github.com/chr1swallace/elisa-paper.

Author contributions

GKH and XCD designed the study and wrote the manuscript with input from co-authors. JA,
TA, JD, SM, GB, MA and SA provided the study serum samples and clinical information. LH,
LPV, AMM, DJS, KCI, BM and GM generated SARS-CoV-2 antigens and pseudotyped
viruses. MF and XCD developed the ELISA protocols and XCD generated the data. DJS and
BM performed the neutralization assay. CW and NFG executed machine learning approaches
and statistical analyses, with input from MCh and BM. MA, SK, PP, MM, JC, MCo and JR
carried out wet lab experiments and assisted with data analysis.
438

439 **Acknowledgments**
440

We would like to thank the study participants and attending clinical teams. Secondly, we extend
our thanks to Björn Reinius, Marc Panas, Julian Stark, Remy M. Muts and Darío Solis Sayago
for their input and discussion. Funding for this work was provided by a Distinguished Professor
grant from the Swedish Research Council (agreement 2017-00968) and NIH (agreement 400
SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC
(MC_UP_1302/5). For the purpose of Open Access, the author has applied a CC BY public
copyright licence to any Author Accepted Manuscript version arising from this submission.

Conflict of interest
450

451 The study authors declare no competing interests related to the work.
452

453 **References**
454

1. Davis, M. M. A Prescription for Human Immunology. *Immunity* vol. 29 835–838
(2008).
2. Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with
Asymptomatic or Mild COVID-19. *Cell* (2020) doi:10.1016/j.cell.2020.08.017.
3. Cervia, C. *et al.* Systemic and mucosal antibody responses specific to SARS-CoV-2
during mild versus severe COVID-19. *J. Allergy Clin. Immunol.* (2020)
doi:10.1016/j.jaci.2020.10.040.
4. Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in
Convalescent Individuals. *Nature* (2020) doi:10.1101/2020.05.13.092619.
5. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for greater than

eight months after infection. *bioRxiv* (2020).

6.   Gudbjartsson, D. F. *et al.* Spread of SARS-CoV-2 in the Icelandic Population. *N. Engl.*
J. Med. (2020) doi:10.1056/nejmoa2006100.

7.   Özçürümez, M. K. *et al.* SARS-CoV-2 antibody testing—questions to be asked. *J.*
Allergy Clin. Immunol. (2020) doi:10.1016/j.jaci.2020.05.020.

8.   Mulligan, M. J. *et al.* Phase I/II study of COVID-19 RNA vaccine BNT162b1 in
adults. *Nature* (2020) doi:10.1038/s41586-020-2639-4.

9.   Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report.
N. Engl. J. Med. (2020) doi:10.1056/nejmoa2022483.

10.   Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity
and correlates of severity. *Science (80-.).* (2020) doi:10.1126/science.abd4250.

11.   Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *British*
Medical Journal (2006) doi:10.1136/bmj.332.7549.1080.

12.   MacCallum, R. C., Zhang, S., Preacher, K. J. & Rucker, D. D. On the practice of
dichotomization of quantitative variables. *Psychol. Methods* (2002) doi:10.1037//1082-
989x.7.1.19.

13.   Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
conformation. *Science (80-.).* (2020) doi:10.1126/science.aax0902.

14.   Hanke, L. *et al.* An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor
interaction. *Nat. Commun.* (2020) doi:10.1038/s41467-020-18174-5.

15.   Herzenberg, L. A. & Herzenberg, L. A. Toward a layered immune system. *Cell* (1989)
doi:10.1016/0092-8674(89)90748-4.

16.   Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19.
Nat. Med. (2020) doi:10.1038/s41591-020-0897-1.

17.   Eto, D. *et al.* IL-21 and IL-6 are critical for different aspects of B cell immunity and
redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. *PLoS*
One **6**, e17739 (2011).

18.   Dienz, O. *et al.* The induction of antibody production by IL-6 is indirectly mediated by
IL-21 produced by CD4 + T cells. *J. Exp. Med.* (2009) doi:10.1084/jem.20081571.

19.   Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell IgG
production in a feed-forward proinflammatory mechanism to skew hematopoiesis and
elevate myeloid production. *Blood* (2010) doi:10.1182/blood-2009-07-230631.

20.   Beagley, K. W. *et al.* Interleukins and IgA synthesis. Human and murine interleukin 6
induce high rate IgA secretion in IgA-committed B cells. *J. Exp. Med.* (1989)

doi:10.1084/jem.169.6.2133.

21.   Bartosch, B. *et al.* In vitro assay for neutralizing antibody to hepatitis C virus:

Evidence for broadly conserved neutralization epitopes. *Proc. Natl. Acad. Sci. U. S. A.*

(2003) doi:10.1073/pnas.2335981100.

22.   Del Valle, D. M. *et al.* An inflammatory cytokine signature predicts COVID-19

severity and survival. *Nat. Med.* (2020) doi:10.1038/s41591-020-1051-9.

23.   Seow, J. *et al.* Longitudinal evaluation and decline of antibody responses in SARS-

CoV-2 infection. *Nat. Microbiol.* (2020) doi:10.1101/2020.07.09.20148429.

24.   Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-

CoV-2 infections. *Nat. Med.* (2020) doi:10.1038/s41591-020-0965-6.

25.   Platt, J. & others. Probabilistic outputs for support vector machines and comparisons to

regularized likelihood methods. *Adv. large margin Classif.* (1999).

26.   Lott, A. & Reiter, J. P. Wilson Confidence Intervals for Binomial Proportions With

Multiple Imputation for Missing Data. *Am. Stat.* (2020)

doi:10.1080/00031305.2018.1473796.

Figure 1: Anti-SARS-CoV-2 Ab phenotypes in COVID-19 patients, PCR+ individuals, blood donors and pregnant women.
(A) OD450nm optical density for anti-S and -RBD IgM, IgG and IgA responses in SARS-CoV-2 PCR+ individuals (*n*=105), blood donors (BD, *n*=500) and pregnant women (PW, *n*=500). A small number of controls for each assay are represented by open circles. **(B)** Circulating IL-6 levels in serum are associated with disease severity. **(C)** Anti-viral antibody levels are associated with disease severity, most pronounced for anti-viral IgA. Anti-S and RBD responses are graphed together. **(D)** Two discordant longitudinal profiles of seroconversion and neutralisation capacity are shown in hospitalized COVID-19 patients. **(E)** *In vitro* pseudotyped virus neutralization ID_{50} titers are associated with disease severity, with the highest titers observed in Cat 3 (ICU) patients. *n*=48 SARS-CoV-2 PCR+ individuals were analyzed in duplicate. **(E)** Comparison of anti-S IgG levels between PCR+ individuals, blood donors (BD) and pregnant women (PW). 3 and 6 SD cut-offs are shown.

Figure 2: Probability-based positivity estimates in blood donors and pregnant women
(A) Distribution of Anti-S and RBD IgG OD values for 595 historical controls (blood donors from Spring 2019). **(B)** Random sub-sampling of non-overlapping negative controls illustrates how the range of negative control (C) values can influence a conventional test cut-off, here 6 SD from the mean of the respective C groups. In the test data, depending on the control values used to set the test threshold for positivity, SP estimates vary by 40%. Blood donor and pregnant women sample values are used as an example. Anti-S IgG values are shown. **(C)** Comparison of probabilistic algorithms suited to ELISA measurements. Logistic regression (LOG), linear discriminant analysis (LDA), support vector machines (SVM) and quadratic SVM. Learners were trained using anti-S and RBD IgG data from 595 negative control values and 138 SARS-CoV-2 PCR+ individuals. Ensemble (*ENS*) learners were generated from the output of SVM-LDA, SVM2-LDA and LOG-LDA, as described. **(D)** Comparisons of specificity and sensitivity for the different probabilistic methods (and SD thresholding) using different cross-validation strategies. **(E)** *ENS* probabilities when applied to healthy donor test data, providing a highly sensitive, specific and consistent multi-dimensional solution to the problem of low responders, and assigning each data point a probability of being positive.

Table 1 – Study samples

SARS-CoV-2 PCR+ individuals[§]	*n*=105
Females	44 (41.9%)
Males	61 (58.1%)
Median age (years)	53.0 (49-61)
Females	51.5 (48-56.2)
Males	55.0 (49-63)
Non-hospitalized (*n*=)	53
Females, males	28, 25
Hospitalized patients (*n*=)	31
Females, males	12, 17
Intensive care (ICU) patients (*n*=)	21
Females, males	3, 17
SARS-CoV2+ PCR (*n*=)	105
Sample collection dates	March-May 2020
SARS-CoV-2 PCR+ KI hospital staff	*n*=33
Sample collection dates	July 2020
Blood donors	*n*=500
Sample collection dates	Weeks 17-21 (March-August) 2020
Pregnant women	*n*=500
Sample collection dates	Weeks 17-21 (March-May) 2020
Historical blood donors	*n*=595
Sample collection dates	March-June 2019
ECV+ donors	*n*=20
Sample collection dates	July-December 2019

[§]*Under the care of Karolinska University Hospital*
No additional metadata available for any samples

Table 1

Figure S1: Antibody phenotypes in PCR+ individuals and healthy participants

(**A**) Study samples used for assay development. (**B**) Anti-S IgM reactivity observed in a random subset of historical controls. Binding was confirmed in these samples in an independent experiment. No reproducible IgG reactivity to S trimers of the RBD was observed across all historical controls in the study. (**C**) Serial dilution of *n*=30 random PCR+ individuals. ECV+ (*n*=4) controls are shown in red. (**D**) Spearman's rank correlation of PCR+ dataset features and antibody levels. DOB - *date of birth*; d-p SymO - *days post-symptom onset*; d-p PCR – *days post SARS-CoV-2+ PCR*; PSV ID50 – *neutralizing titer.* (**E**) Adjusted fold-change compared to Category 1 PCR+ individuals. The effects of age (DOB), sex, days from PCR test were considered.